Neurosearch mit neuer Allianz - 500 Beiträge pro Seite

[dottore]

NeuroSearch and Janssen Pharmaceutica, a division of the Johnson & Johnson group, have signed an agreement to collaborate on the discovery and development of new medicines to treat central nervous system (CNS) diseases.

NeuroSearch will be responsible for the drug discovery programmes as well as for the early development of the drug candidates. Janssen will then have various options to exercise license rights to the individual compounds.

NeuroSearch CEO Flemming Pedersen said that combined drug discovery expertise and activities would provide an optimal framework for the development and commercialisation of new and better CNS medicines.

"We believe the agreement will significantly boost our pipeline of products, representing a substantial value potential for NeuroSearch," Flemming said.

On exercise of license options, Janssen will be responsible for and finance all subsequent development and commercialisation activities. NeuroSearch will be entitled to milestone payments of up to â¬213m plus double-digit royalties on global sales for each product successfully developed and commercialised under the alliance.

NeuroSearch will also receive funding of â¬32m in the first three years, including an upfront equity investment of â¬10m and a share put option of â¬5m from Janssen.

In addition, NeuroSearch will receive milestone payments plus royalties on global sales for each compound successfully commercialised.

The agreement will run for three years with an option for Janssen to extend the alliance.

[dottore]

Neurosearch stellt sich selbst wie folgt vor:
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the Nasdaq OMX Copenhagen A/S.



The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders.

A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Company, Janssen Pharmaceutica and GlaxoSmithKline (GSK), and a license collaboration with Abbott.



NeuroSearch’s pipeline of drug candidates comprises seven clinical (Phase I-III) development programmes: Pridopidine (ACR16) for Huntington’s disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 to treat dyskinesias in Parkinson’s disease (Phase Ib), ACR343 for schizophrenia (Phase II ready), ABT-560 for the treatment of various CNS disorders (Phase I) in collaboration with Abbott, and NSD-788 for anxiety/depression (Phase I).


In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.

The company has approximately 220 employees with activities in Ballerup and Gothenburg.

[dottore]

da noch was leckeres!

13 August 2009 - Announcement

NeuroSearch (NEUR) announces that today 345,238 new shares of DKK 20 nominal value each, corresponding to a total nominal capital increase of DKK 6,904,760, have been issued. The new shares have been registered with the Danish Commerce and Companies Agency. As announced in announcement no. 31-09 from 4 August 2009, all the new shares have been subscribed by GlaxoSmithKline (GSK) at a market price of DKK 107.84 per share of DKK 20 nominal value each.

The net proceeds to NeuroSearch from the directed offering to GSK amount to DKK 37.2 million.

The 345,238 new shares have been issued without pre-emption rights for the company's current shareholders. The issue has been decided by the Board of Directors in NeuroSearch on the basis of Article 5 of the company’s Articles of Association authorising the Board of Directors to increase the share capital of the company. The new shares will rank pari passu with and have the same rights as the existing shares in the company.

Following registration of the new shares, NeuroSearch's share capital amounts to DKK 332,385,360 (16,619,268 shares of DKK 20 nominal value each).

As of today, the new shares have been admitted to trading and official listing on NASDAQ OMX Copenhagen under the ISIN of NeuroSearch’s existing shares (ISIN DK0010224666).



Flemming Pedersen

CEO

[dottore]

und noch ein Leckerli!

Shareholdervalue ist ein wichtiges Ziel des Managements. Es werden eigene Aktien zurück gekauft, weil bereits in weniger als 12 Monaten mit der Zulassung des Wirkstoffes für die Huntington-Krankheit gerechnet wird. Damit werden aber auch Verbindlichkeiten fällig, die für den Erwerb des Wirkstoffs ausgehandelt wurden. Danach können die 200 Mio dann in bar oder in Aktien bezahlt werden. Es liegt auf der Hand, das hier ein Interesse an höheren Kursen besteht. Und wenn die Zulassung kommt, wird es erst einmal eine satte Reaktion an der Börse geben. Alöso ist es sinnvoll schon vorher eingesammelt zu haben.

Hauptmarkt Nasdaq.Copenhagen

strong buy

[dottore]

NeuroSearch successfully advances NSD-721 for treatment of social anxiety disorder and receives EUR 5 million in equity financing under the alliance with GlaxoSmithKline

04 August 2009 - Announcement

- NeuroSearch exercises option to issue shares worth EUR 5 million to GlaxoSmithKline
- The share issue will consist of 345,238 new shares at a price of DKK 107.84 per share
- NeuroSearch will receive additional EUR 4 million in cash upon Phase I initiation

Copenhagen, 4 August 2009 – NeuroSearch (NEUR) has successfully completed the preclinical development of NSD-721, a selective GABAA receptor modulator, and is now advancing this novel drug candidate into clinical studies for the treatment of social anxiety disorder under the alliance with GlaxoSmithKline (GSK). An Investigational New Drug (IND) application has been filed and approved, and NeuroSearch plans for the initiation of Phase I studies with NSD-721 within the near future.

Under the terms of the alliance agreement, upon the filing of an IND application for NSD-721 NeuroSearch has the option to issue new shares to GSK at market price with a value of EUR 5 million, equal to DKK 37 million, based on the EURKK exchange rate of the Danish Central Bank as of 31 July 2009. Hence, NeuroSearch has decided to issue 345,238 new NeuroSearch shares to GSK to be subscribed at a price of DKK 107.84 per share, corresponding to proceeds of DKK 37,230,500 (EUR 5 million) to NeuroSearch.

Further, under the agreement NeuroSearch will receive EUR 4 million (DKK 30 million) as milestone payment upon the initiation of Phase I studies with NSD-721.

The alliance with GSK covers a number of drug candidates, including NSD-721. Under the terms of the alliance agreement, NeuroSearch has the option to issue new shares to GSK at market price for a total amount of up to EUR 20 million (DKK 149 million), to be exercised in four equal tranches upon the filing of IND applications for drug candidates developed under the agreement. Furthermore, NeuroSearch is entitled to milestone payments of up to EUR 109 million (DKK 812 million) plus royalties of net sales per product developed and marketed under the agreement.

Flemming Pedersen, CEO at NeuroSearch comments;
“We are very pleased to announce the advancement of the novel drug candidate NSD-721 into clinical development for the treatment of social anxiety disorder under our alliance with GSK. The related income and financing of EUR 9 million in total adds to our already strong financial capabilities and allows us to progress both NSD-721 and other valuable assets in our pipeline.“

[dottore]

der festgestellte Kurs ist schon 1 € UNTER dem Bid

Man sollte doch in Kopenhagen handeln, wenn man kann. Jedenfalls entwickelt sich der Kurs endlich wie gewünscht.
Einstieg bei 125, jetzt 137 dän Kronen

[dottore]

Außerordentliche HV am Freitag 18. Sept. zur Genehmigung einer Kapitalerhöhung mit Bezugsrechten für Aktieninhaber
(ohne Gewähr, da mein Englisch nicht 100% sicher ist)

[dottore]

heute am Haupthandelsplatz schon wieder 10% hoch. Die Kapitalerhöhung wird gut angenommen!